Publications by authors named "D Check"
Introduction: Opioids and benzodiazepines are commonly prescribed for cancer symptoms. In combination, they can increase the risk of adverse events, particularly for older adults with multimorbidity, who represent most patients with cancer. We aimed to understand cancer care providers' practices for opioid and benzodiazepine coprescribing and mitigating potential harms.
View Article and Find Full Text PDFNon-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.
View Article and Find Full Text PDFArticle Synopsis
- * Current risk prediction models for ovarian cancer show limited effectiveness, with accuracy scores ranging from 0.58 to 0.65, indicating a need for improvement in identifying at-risk populations.
- * Proposed thresholds for preventive surgery are around a 4% lifetime risk, yet the average predicted risk in the general population is only 0.6-2.5%, pointing to a gap in prevention strategies for lower-risk individuals.
While considerable scholarship has explored responsibilities owed to research participants at the conclusion of explanatory clinical trials, no guidance exists regarding responsibilities owed at the conclusion of a pragmatic clinical trial (PCT). Yet post-trial responsibilities in PCTs present distinct considerations from those emphasized in existing guidance and prior scholarship. Among these considerations include the responsibilities of the healthcare delivery systems in which PCTs are embedded, and decisions about implementation for interventions that demonstrate meaningful benefit following their integration into usual care settings-or deimplementation for those that fail to do so.
View Article and Find Full Text PDFBackground: Substance misuse is common among cancer survivors and can negatively impact cancer outcomes.
Methods: We conducted a cross-sectional study using National Survey on Drug Use and Health data for 2015 to 2020. We included adult respondents with a history of solid tumor cancer.